With Samsung's Push For MabThera Biosimilar, Roche Persists On Call For Strengthened Regulatory Framework
This article was originally published in PharmAsia News
Executive Summary
SEOUL - In reaction to South Korean firm Samsung Electronics' recent clinical trial application for its biosimilar of Roche's MabThera, Roche said that it supports developing a regulatory framework for biosimilars that would apply the same stringent standards as those applied to originator products to ensure the protection of public health